Cyramza
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Cyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature. The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis. Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.
CONTENTS
5 OVERVIEW
5 Drug Overview
6 Product Profiles
6 Cyramza : Hepatocellular carcinoma (HCC)
15 Cyramza : Non-small cell lung cancer (NSCLC)
28 Cyramza : Gastric cancer
41 Cyramza : Colorectal cancer (CRC)
55 Cyramza : Bladder cancer
LIST OF FIGURES
11 Figure 1: Datamonitor Healthcare’s drug assessment summary of Cyramza for HCC
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Cyramza for HCC
14 Figure 3: Cyramza sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
20 Figure 4: Cyramza for non-small cell lung cancer – SWOT analysis
21 Figure 5: Datamonitor Healthcare’s drug assessment summary for Cyramza in non-small cell lung cancer
22 Figure 6: Datamonitor Healthcare’s drug assessment summary for Cyramza in non-small cell lung cancer
24 Figure 7: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
32 Figure 8: Cyramza for gastric cancer – SWOT analysis
33 Figure 9: Datamonitor Healthcare’s drug assessment summary of Cyramza for gastric cancer
34 Figure 10: Datamonitor Healthcare’s drug assessment summary of Cyramza for gastric cancer
36 Figure 11: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
46 Figure 12: Cyramza for colorectal cancer – SWOT analysis
47 Figure 13: Datamonitor Healthcare’s drug assessment summary of Cyramza for colorectal cancer
48 Figure 14: Datamonitor Healthcare’s drug assessment summary of Cyramza for colorectal cancer
50 Figure 15: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
59 Figure 16: Cyramza for urothelial bladder cancer – SWOT analysis
60 Figure 17: Datamonitor Healthcare’s drug assessment summary for Cyramza in urothelial bladder cancer
61 Figure 18: Datamonitor Healthcare’s drug assessment summary for Cyramza in urothelial bladder cancer
LIST OF TABLE
6 Table 1: Recent high-impact events for Cyramza in HCC
7 Table 2: Cyramza drug profile
7 Table 3: Approval history of Cyramza for HCC in the US, Japan, and five major EU markets
9 Table 4: Trials of Cyramza for HCC
10 Table 5: Cyramza for HCC – SWOT analysis
15 Table 6: Cyramza drug profile
17 Table 7: Cyramza pivotal trial data in non-small cell lung cancer
19 Table 8: Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
25 Table 9: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
27 Table 10: Cyramza patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
29 Table 11: Cyramza drug profile
30 Table 12: Cyramza pivotal trial data in gastric cancer
37 Table 13: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
39 Table 14: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
41 Table 15: Cyramza drug profile
43 Table 16: Cyramza Phase III data in colorectal cancer
45 Table 17: Cyramza Phase I trials in colorectal cancer
51 Table 18: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
53 Table 19: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
56 Table 20: Cyramza drug profile
57 Table 21: Cyramza Phase III trial in urothelial bladder cancer
58 Table 22: Cyramza early-phase data in urothelial bladder cancer
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Opdivo 
Sign up to the